Literature DB >> 10810467

Review of cellular mechanisms of tumor osteolysis.

D R Clohisy1, S L Perkins, M L Ramnaraine.   

Abstract

The cellular and biochemical mechanisms that direct the destruction of bone at sites of tumor osteolysis are unknown. To better understand the mechanisms through which tumors direct bone resorption, research has focused on developing in vivo and in vitro experimental models that are useful for studying this process. In vivo experimental systems have been developed that permit study of tumor osteolysis from human and murine tumors, and that permit the study of tumors that arise from (sarcoma) or can metastasize (breast cancer) to bone. Recent research has focused on three questions: (1) Are osteoclasts or tumor cells responsible for bone resorption during tumor osteolysis? (2) What are the cellular mechanisms that are responsible for bone resorption during tumor osteolysis, and (3) what are the tumor cell products that regulate the cellular mechanisms that are responsible for tumor osteolysis? It has been determined that osteoclasts are responsible for bone resorption at sites of tumor osteolysis by enhancing the binding of osteoclast to bone, by inducing osteoclastic bone resorption, and by stimulating osteoclast formation. Attempts to identify tumor cell products that regulate these cellular mechanisms are in progress, and findings suggest that production of macrophage colony stimulating factor may be required for tumor osteolysis to occur with some tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810467     DOI: 10.1097/00003086-200004000-00013

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  17 in total

Review 1.  Manipulating the environment of cancer cells in bone: a novel therapeutic approach.

Authors:  T John Martin
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 2.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 3.  Bone pain mechanism in osteoporosis: a narrative review.

Authors:  Consalvo Mattia; Flaminia Coluzzi; Ludovica Celidonio; Renato Vellucci
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

4.  Cancer pain physiology.

Authors:  Sarah Falk; Kirsty Bannister; Anthony H Dickenson
Journal:  Br J Pain       Date:  2014-11

5.  Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer.

Authors:  Dongxing Ji; Zhiyong Liang; Guixin Liu; Guangzong Zhao; Jun Fang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-08-24       Impact factor: 3.000

6.  Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.

Authors:  S Lhoták; L J Elavathil; S Vukmirović-Popović; W C Duivenvoorden; R G Tozer; G Singh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 7.  Bone cancer pain: from mechanism to therapy.

Authors:  Patrick W Mantyh
Journal:  Curr Opin Support Palliat Care       Date:  2014-06       Impact factor: 2.302

Review 8.  Managing Pain in the Older Cancer Patient.

Authors:  Dylan Finnerty; Áine O'Gara; Donal J Buggy
Journal:  Curr Oncol Rep       Date:  2019-11-14       Impact factor: 5.075

9.  Topical treatment with Tong-Luo-San-Jie gel alleviates bone cancer pain in rats.

Authors:  Juyong Wang; Ruixin Zhang; Changsheng Dong; Liying Jiao; Ling Xu; Jiyong Liu; Zhengtao Wang; Qi Liang Mao Ying; Harry Fong; Lixing Lao
Journal:  J Ethnopharmacol       Date:  2012-08-30       Impact factor: 4.360

10.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Authors:  Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.